Health Data Insight CIC

🚨Don’t miss out – only one week to go!🚨 Our 2025 Health Data Insight CIC #Interns Programme application deadline is Monday 2nd of December 2024. Go to https://lnkd.in/e3UbfGyv for further information and to apply for this amazing opportunity. #innovate #teamwork

It’s not all hard work on the Health Data Insight CIC Internship Programme! This year’s #interns enjoyed team bonding and a relaxing day of punting on the beautiful River Cam. Interested in joining us next summer? Learn more and apply here 👉 https://lnkd.in/e2NAXwBx #Internship #Teamwork

From building a synthetic data service to developing innovative tools that shape the future of healthcare. Learn more about the invaluable skills and insights you could gain on the Health Data Insight CIC #Interns Programme 👉 https://lnkd.in/e3UbfGyv #HealthData #Innovation 

Students from University of Birmingham, University of Cambridge, University of Dundee, Durham University, Imperial College London, University of Liverpool, UCL, University of Oxford, and University of Southampton have all enjoyed our Health Data Insight CIC #Internship Programme.   Apply now for Summer 2025 👉https://lnkd.in/e3UbfGyv

Want to learn more about the Health Data Insight CIC #Internship Programme? Watch this short video from our 2021 #interns sharing their journey! It might just inspire you to join us! 👉 https://lnkd.in/e5Ht7qQ3

Publication news! A new study commissioned by Kidney Cancer UK and conducted by Health Data Insight CIC using data from the NHS England National Disease Registration Service, titled "Variability in Kidney Cancer Treatment and Survival in England: Results of a National Cohort Study," has been published in Clinical Oncology. The study co-authored by HDI Senior Health Data Analyst Clare Pearson and Principal Health Data Analyst Craig Knott, analysed data from over 18,000 patients diagnosed with primary kidney cancer (KC) between 2017 and 2018. Variations in the delivery of surgery and systemic anti-cancer therapy (SACT) across Cancer Alliances and NHS trusts were shown, even after adjusting for patient factors such as age and comorbidities. For example, radical nephrectomy rates for early-stage kidney cancer varied from 53% to 80%, while SACT for metastatic disease ranged from 40% to 71%. with survival rates overall being higher for those receiving SACT. There are likely to be many reasons for variations in practice. These findings will contribute to the development of national guidelines to standardise care and improve outcomes, with efforts already underway through the Getting It Right First Time (GIRFT) Academy practical guide to a good practice pathway, development of NICE guidelines, and the National Kidney Cancer Audit. These will provide a robust framework for improving equity of access and outcomes. To read more go to 👉 https://lnkd.in/eu-EKU9f #KidneyCancer #CancerData

Join our Health Data Insight CIC #Interns Programme to develop your skills and gain hands-on experience in the world of healthcare innovation!  To learn more and apply for Summer 2025 visit https://lnkd.in/e3UbfGyv #HealthData #Innovation

🔍 Curious about the innovative work of our 2024 #Interns at Health Data Insight CIC? This year, they tackled the challenge of tracking hospital equipment using low-cost, low-tech solutions, which could make a real impact to the future of healthcare!💡 Discover more about their journey and the solutions they developed: https://lnkd.in/euQB3QjW #Innovation #HealthcareTechnology

🚀 Applications for our 2025 Health Data Insight CIC #Interns Programme are now live! 🚀 Application deadline is 2nd December 2024. For further information, and to apply, visit our website 👉 https://lnkd.in/e3UbfGyv

📢Publication news! A new study, co-authored by Health Data Insight CIC Principal Health Data Analyst Craig Knott, titled "Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study," has been published in Urologic Oncology: Seminars and Original Investigations.  The study explored anticancer treatment patterns for patients diagnosed with advanced urothelial carcinoma in England between 2013 and 2019, using data collected by the NHS England National Disease Registration Service. Key findings:  - 69% of patients did not receive treatment (within the range reported across other real-world studies of European populations)  - Female sex, older age, poor performance status, greater comorbidities, and living in income-deprived areas were linked to lower treatment rates.  - 91% of treated patients received platinum-based chemotherapy  - Although advanced urothelial carcinoma has a poor prognosis, median overall survival was significantly different between treated (19.9 months) and untreated (5.8 months) patients. The findings highlight a need for further investigation into possible multifactorial reasons for treatment disparities, and whether the introduction of newer therapies will boost treatment rates and improve patient survival.  To read more go to 👉https://lnkd.in/ewEghpDt #UrologicalCancerAwarenessMonth #CancerData